News & Updates

The selective autotaxin inhibitor ziritaxestat shows therapeutic potential in patients with early diffuse cutaneous systemic sclerosis, conferring greater reductions in modified Rodnan skin score compared with placebo and potentially reducing fibrosis, according to data from the phase IIa NOVESA study.

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.

In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.

In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.

The herbal combination of curcumin plus QingDai (CurQD) appears beneficial to patients with active ulcerative colitis (UC), with a recent study showing that the combination induced clinical and biomarker remission.